Overview and Scope
Difficult-to-express proteins refer to proteins that are challenging to produce in large quantities or with high yield using standard protein expression systems in heterologous expression systems. These proteins are used in research studies to explore protein folding and stability, generate innovative therapeutics, and conduct biochemical studies of drugs.
Sizing and Forecast
The difficult-to-express proteins market size has grown rapidly in recent years. It will grow from $4.11 billion in 2023 to $4.63 billion in 2024 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to rising demand for protein therapeutics, drug development challenges, biopharmaceutical advancements, technological limitations, gene editing and engineering.
The difficult-to-express proteins market size is expected to see rapid growth in the next few years. It will grow to $7.09 billion in 2028 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to novel expression systems development, next-generation gene editing tools, improved cell-free systems, enhanced protein engineering, ai and machine learning integration. Major trends in the forecast period include innovative protein folding technologies, expanded use of synthetic biology, targeted protein modification, biophysical characterization advances, increased use of crispr/cas technology.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/difficult-to-express-proteins-global-market-report
Segmentation & Regional Insights
The difficult-to-express proteins market covered in this report is segmented –
1) By Protein: Proteases, Kinases, Membrane Proteins, Other Proteins
2) By Expression Of Difficult Proteins: Disulfide-bonded Protein Expression, Membrane Protein Expression, Toxic Protein Expression, Target Protein Insolubility
3) By Technology: Cell-free Protein Synthesis, Prokaryotic Expression Systems, Small Ubiquitin-like Modifier (SUMO) Fusion System, Gene Fusion Systems, Other Technologies
4) By Application: Drug Discovery, Protein Purification, Protein Therapeutics, Disease Diagnostics And Monitoring, Other Applications
North America was the largest region in the difficult-to-express proteins market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the difficult-to-express proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12602&type=smp
Major Driver Impacting Market Growth
Rising demand for recombinant proteins is expected to propel the growth of the difficult-to-express protein market going forward. Recombinant protein is created using recombinant DNA (deoxyribonucleic acid), or DNA that has undergone modification to produce the genetic code of a protein of desire. Difficult-to-express proteins are used in recombinant protein synthesis to examine their specific activities, protein-protein interactions, and the development of innovative therapeutics for complex medical diseases. For instance, in 2022, according to the annual report published by Amgen Inc., a US-based biopharmaceutical company, Prolia (Denosumab), a recombinant human monoclonal antibody (protein), witnessed 12% growth in annual sales, generating $3,628 million in 2022, compared with $3,248 million in 2021. Therefore, the rising demand for recombinant proteins propels the growth of the difficult-to-express protein market.
Key Industry Players
Major companies operating in the difficult-to-express proteins market report are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group Ltd, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Samsung Biologics Co. Ltd., Bio-Techne Corp., GenScript Biotech Corporation, Ajinomoto Bio-Pharma Services, Novasep Holding SAS, Rentschler Biopharma SE, BioLegend Inc., Codexis Inc., Enzo Biochem Inc., Sino Biological Inc., Horizon Discovery Ltd., Creative Biolabs Inc., OriGene Technologies Inc., Celonic AG, Cube Biotech GmbH, Lucigen Corporation, Batavia Biosciences Inc., Cytovance Biologics Inc., Alloy Therapeutics Inc., Aragen Bioscience Inc., Selexis SA, LifeSensors Inc., Bionova Scientific Inc.
The difficult-to-express proteins market report table of contents includes:
1. Executive Summary
2. Difficult-to-Express Proteins Market Characteristics
3. Difficult-to-Express Proteins Market Trends And Strategies
4. Difficult-to-Express Proteins Market – Macro Economic Scenario
5. Global Difficult-to-Express Proteins Market Size and Growth
.
.
.
32. Global Difficult-to-Express Proteins Market Competitive Benchmarking
33. Global Difficult-to-Express Proteins Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Difficult-to-Express Proteins Market
35. Difficult-to-Express Proteins Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
